Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | $185.00K | $123.00K |
| Gross Profit | N/A | N/A | N/A | N/A | $-185.00K | $-123.00K |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Expenses | $158.83M | $114.36M | $71.66M | $43.22M | $17.01M | $9.80M |
| Operating Income | $-158.83M | $-114.36M | $-71.66M | $-43.22M | $-17.19M | $-9.92M |
| Operating Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income | $-133.81M | $-100.16M | $-67.64M | $-42.81M | $-17.05M | $-9.49M |
| Net Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS (Basic) | $-1.45 | $-1.57 | $-1.26 | $-0.86 | $-0.35 | $-0.19 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A |